$GNPX
Genprex Inc

2018 Q2 Form 10-Q Financial Statement

#000156459018021749 Filed on August 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.920M $1.080M
YoY Change 448.15% -46.27%
% of Gross Profit
Research & Development $113.0K $105.0K
YoY Change 7.61% 31.22%
% of Gross Profit
Depreciation & Amortization $1.171K $0.00
YoY Change
% of Gross Profit
Operating Expenses $113.0K $105.0K
YoY Change 7.61% -94.98%
Operating Profit -$6.036M -$1.181M
YoY Change 411.02%
Interest Expense $30.58K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.060M -$1.180M
YoY Change 413.56% -43.54%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.061M -$1.181M
YoY Change 413.15% -43.48%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$448.6K -$72.88K
COMMON SHARES
Basic Shares Outstanding 13.90M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.00M $470.0K
YoY Change 2453.19%
Cash & Equivalents $12.00M $467.9K
Short-Term Investments
Other Short-Term Assets $540.0K $30.00K
YoY Change 1700.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $12.54M $500.0K
YoY Change 2408.0%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $10.00K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles $323.1K
YoY Change
Long-Term Investments
YoY Change
Other Assets $336.6K $220.0K
YoY Change 52.98%
Total Long-Term Assets $350.9K $510.0K
YoY Change -31.19%
TOTAL ASSETS
Total Short-Term Assets $12.54M $500.0K
Total Long-Term Assets $350.9K $510.0K
Total Assets $12.89M $1.010M
YoY Change 1176.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K $170.0K
YoY Change 76.47%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $40.00K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $300.5K $210.0K
YoY Change 43.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $300.5K $210.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $300.0K $210.0K
YoY Change 42.86%
SHAREHOLDERS EQUITY
Retained Earnings -$24.21M
YoY Change
Common Stock $13.90K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.59M $800.0K
YoY Change
Total Liabilities & Shareholders Equity $12.89M $1.010M
YoY Change 1176.33%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$6.061M -$1.181M
YoY Change 413.15% -43.48%
Depreciation, Depletion And Amortization $1.171K $0.00
YoY Change
Cash From Operating Activities -$3.110M -$670.0K
YoY Change 364.18% 644.44%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$20.00K
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$20.00K
YoY Change 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.11M 230.0K
YoY Change 6469.57% 475.0%
NET CHANGE
Cash From Operating Activities -3.110M -670.0K
Cash From Investing Activities -20.00K -20.00K
Cash From Financing Activities 15.11M 230.0K
Net Change In Cash 11.98M -460.0K
YoY Change -2704.35% 820.0%
FREE CASH FLOW
Cash From Operating Activities -$3.110M -$670.0K
Capital Expenditures -$20.00K -$20.00K
Free Cash Flow -$3.090M -$650.0K
YoY Change 375.38% 622.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
13411
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
0
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
323139
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
336550
CY2018Q2 us-gaap Assets
Assets
12890910
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5921950
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
300537
CY2018Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2017Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
201890
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
300537
CY2018Q2 gnpx Investment Unit
InvestmentUnit
0
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
13897
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36784040
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24207564
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
12590373
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12890910
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13896926
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13896926
CY2018Q2 us-gaap Revenues
Revenues
0
us-gaap Depreciation
Depreciation
2118
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112969
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
104979
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
164590
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1075407
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6556011
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
6036090
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
1181194
us-gaap Costs And Expenses
CostsAndExpenses
6722719
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6036090
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1181194
us-gaap Operating Income Loss
OperatingIncomeLoss
-6722719
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5461
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19
us-gaap Investment Income Interest
InvestmentIncomeInterest
5489
CY2018Q2 us-gaap Interest Expense
InterestExpense
30584
CY2017Q2 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
37982
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6061213
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1181175
us-gaap Net Income Loss
NetIncomeLoss
-6755212
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13507942
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11480417
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12636316
us-gaap Share Based Compensation
ShareBasedCompensation
3527656
us-gaap Share Based Compensation
ShareBasedCompensation
876696
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8844
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
515137
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8154
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-13411
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-759591
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
199213
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-328535
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-75656
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3314086
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1321092
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8523
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5889
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
24570
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
36344
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33093
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42233
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
201890
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15389353
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
228974
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15187463
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
228974
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11840283
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1134351
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161251
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1602295
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12001535
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
467944
us-gaap Interest Paid Net
InterestPaidNet
10645
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates</font></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of our condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p></div>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6.6841954
CY2018Q2 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2018Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
11751535
CY2017Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0
CY2018Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2017Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q2 gnpx Number Of Patents
NumberOfPatents
30
gnpx Number Of Pending Patents
NumberOfPendingPatents
2
CY2018Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
4500000
CY2018Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2020-08-13
us-gaap Debt Instrument Description
DebtInstrumentDescription
If no event of default occurs prior to August 13, 2020, the Promissory Note and all related interest will be cancelled.
gnpx Warrant Right To Purchase Percentage
WarrantRightToPurchasePercentage
0.80
gnpx Warrant Discount Rate
WarrantDiscountRate
0.20
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2013Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2500000
CY2014Q1 gnpx Conversion Of Stock Shares Issued And Forward Stock Split
ConversionOfStockSharesIssuedAndForwardStockSplit
1235219
CY2018Q2 gnpx Warrant To Purchase Shares Of Common Stock
WarrantToPurchaseSharesOfCommonStock
38400
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
66842
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
343755
CY2017 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
207206
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1095230
CY2017Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
150211
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 gnpx Non Voting Common Stock Conversion Ratio
NonVotingCommonStockConversionRatio
1
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2628749
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3707366
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M9D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2628749
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1078617
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.80
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.78
gnpx Longterm Contract Estimated Cost
LongtermContractEstimatedCost
2000000
gnpx Royalty On Sales Percentage
RoyaltyOnSalesPercentage
0.01
gnpx Royalty Term
RoyaltyTerm
P21Y
gnpx Royalty Payment Annual Minimum
RoyaltyPaymentAnnualMinimum
20000
CY2018Q2 us-gaap Other Commitment
OtherCommitment
191393
CY2016 us-gaap Legal Fees
LegalFees
15393
CY2016Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
176000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
140000
CY2017Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
36000
CY2017Q1 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
120000
CY2017Q1 gnpx Accrued Patent Costs Current
AccruedPatentCostsCurrent
36000
CY2017Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
20000
CY2016 us-gaap Other Expenses
OtherExpenses
36000
CY2017Q2 us-gaap Payments For Royalties
PaymentsForRoyalties
20000
CY2017Q2 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
240000
CY2017Q2 gnpx Contingent Payments Annual Increase
ContingentPaymentsAnnualIncrease
20000
CY2017Q1 gnpx Contingent Consideration Liability Operating Activities
ContingentConsiderationLiabilityOperatingActivities
240000
CY2017Q1 gnpx Fixed Contingent Consideration Liability Operating Activities
FixedContingentConsiderationLiabilityOperatingActivities
120000
CY2017Q1 us-gaap Finite Lived Intangible Assets Period Increase Decrease
FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
-120000
CY2017Q4 gnpx Percentage Applied On Outstanding Shares For Warrant To Purchase Shares Of Common Stock
PercentageAppliedOnOutstandingSharesForWarrantToPurchaseSharesOfCommonStock
0.03
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.34
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
8000000

Files In Submission

Name View Source Status
0001564590-18-021749-index-headers.html Edgar Link pending
0001564590-18-021749-index.html Edgar Link pending
0001564590-18-021749.txt Edgar Link pending
0001564590-18-021749-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-10q_20180630.htm Edgar Link pending
gnpx-20180630.xml Edgar Link completed
gnpx-20180630.xsd Edgar Link pending
gnpx-20180630_cal.xml Edgar Link unprocessable
gnpx-20180630_def.xml Edgar Link unprocessable
gnpx-20180630_lab.xml Edgar Link unprocessable
gnpx-20180630_pre.xml Edgar Link unprocessable
gnpx-ex101_59.htm Edgar Link pending
gnpx-ex311_6.htm Edgar Link pending
gnpx-ex312_7.htm Edgar Link pending
gnpx-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending